Lasa Supergenerics share price
NSE: LASABSE: 540702Pharmaceuticals & BiotechnologySmall Cap
Lasa Supergenerics Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2017
Last close ₹4.67down ₹0.24 (4.89%)BSE ₹5.03
Share price at the NSE close on 26 Oct 2026. Previous close ₹4.91.
26 Oct: open ₹4.86, high ₹4.86, low ₹4.67
52-week range of traded prices to 26 Oct 2026
₹4.67Low, 26 Oct 2026₹12.48High, 5 Jan 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹23 Cr3,595th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.47
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −24.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −24.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 42,091
Results
Standalone; ₹ crore.Lasa Supergenerics quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −95.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. Under it, revenue in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹1.23 CrQuarter to Mar 2026: −₹0.13 Cr
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹3.58 CrQuarter to Mar 2026: −₹4.16 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −291.7%
Revenue by quarter
- Revenue
- Loss
Peak revenue ₹39 Cr, quarter to Sep 2024; lowest −₹0.13 Cr, quarter to Mar 2026
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 7 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.4 | 33.1 | 39.1 | 20.0 | 3.1 | 2.2 | −0.1 | 1.2 |
| Net profit | −3.2 | 5.5 | −14.3 | −21.1 | −6.3 | −2.6 | −4.2 | −3.6 |
| Net margin | −8.2% | 16.6% | −36.5% | −105.5% | −204.2% | −116.2% | 3,166.8% | −291.7% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹25 Crdown 82.35%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹34 CrYear to Mar 2025: −₹15 Cr
- Net margin
- −135.6%
Revenue by year
Peak revenue ₹246 Cr, year to Mar 2018; lowest ₹25 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 6 of the 9 years shown
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 246what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹2.31 crore, a tax on the goods the company makes that it collects and pays to the government. | 170 | 167 | 202 | 137 | 130 | 104 | 142 | 25 |
| Net profit | 12 | −12 | 4 | 23 | −5 | −39 | −22 | −15 | −34 |
| Net margin | 5.0% | −7.1% | 2.2% | 11.3% | −3.9% | −29.8% | −20.8% | −10.4% | −135.6% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Equity, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −66.4% | – | – | 0.0% |
| 3 years | −32.6% | – | – | 0.0% |
| 5 years | −37.5% | – | – | 0.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Lasa Supergenerics competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Lasa Supergenerics in market cap. Lasa Supergenerics' own figures are from its last trade, on 26 Oct 2026. 2 companies in the table last traded before then: their rows are priced on their last trade.Healthcare companies
Lasa Supergenerics is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sunrest LifescienceSUNREST | 29 | 6.98 | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 28 | – | 1.10 | – | – | – | −0.7% | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 23 | – | – | – | – | – | – | 0.00% |
 Walpar NutritionsWALPAR | 23 | 9.49 | 1.24 | +9.8% | −42.7% | 14.0% | – | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 22 | 31.58 | 1.93 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
 Centuple GlobalCENTUPLE | 20 | 16.49 | 9.86 | +4,540.6% | +1,281.3% | 94.1% | 22.8% | 0.00% |
 Zenith Health CareZENITHHE | 19 | 121.25 | 2.61 | −9.3% | – | 2.2% | −1.2% | 0.00% |
 Colinz LaboratoriesCOLINZ | 17 | 6.22 | 1.73 | −8.4% | +484.3% | 28.7% | 1.7% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Lasa Supergenerics dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.25 a share, years to Mar 2021 and Mar 2022.
| Ex-date | Type | Per share |
|---|---|---|
| 16 Sep 2022 | Final | ₹0.25 |
| 15 Sep 2021 | Final | ₹0.25 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Lasa Supergenerics announcements
Oct 2026
Sep 2026
30 Sep · Meeting
9 Sep · Meeting
9 Sep · Board meeting
Lasa Supergenerics share price by year
Each calendar year to 2025.Lasa Supergenerics share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 9.44 | −62.9% | 29.70 | 8.22 |
| 2024 | 25.44 | −14.9% | 39.30 | 20.00 |
| 2023 | 29.90 | −11.1% | 32.85 | 17.65 |
| 2022 | 33.65 | −50.9% | 80.20 | 25.70 |
| 2021 | 68.60 | −18.9% | 94.85 | 56.05 |
| 2020 | 84.60 | +372.6% | 88.05 | 18.60 |
| 2019 | 17.90 | −40.6% | 34.85 | 9.75 |
| 2018 | 30.15 | −83.3% | 208.85 | 17.10 |
| 2017 | 180.95 | – | 180.95 | 128.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 21 Sep 2017.
Recent sessions
The 9 trading days to 19 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 19 Oct 2026 | 5.16 | 5.39 | 4.91 | 4.91 | 4.93 | 37,588 | – |
| 12 Oct 2026 | 5.06 | 5.58 | 5.06 | 5.16 | 5.22 | 1,66,935 | – |
| 5 Oct 2026 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 59,554 | – |
| 28 Sep 2026 | 5.60 | 5.60 | 5.60 | 5.60 | 5.60 | 21,802 | – |
| 21 Sep 2026 | 5.89 | 5.89 | 5.89 | 5.89 | 5.89 | 17,769 | – |
| 15 Sep 2026 | 6.20 | 6.20 | 6.20 | 6.20 | 6.20 | 18,314 | – |
| 9 Sep 2026 | 6.71 | 6.71 | 6.45 | 6.52 | 6.62 | 46,913 | 88.6% |
| 8 Sep 2026 | 6.70 | 6.83 | 6.65 | 6.69 | 6.70 | 35,670 | 90.9% |
| 7 Sep 2026 | 6.73 | 6.80 | 6.60 | 6.68 | 6.71 | 17,590 | 90.7% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- LASA
- BSE code
- 540702
- ISIN
- INE670X01014
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.lasalabs.com
- CIN
- L24233MH2016PLC274202
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2016
- Registered office
- C-105, MIDC, Mahad 402301, Maharashtra
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments